Global vaccine and health bodies could team up more to tackle US-led funding crisis
LONDON - Two global health groups that fund billions of dollars worth of critical medical aid - from childhood vaccines to malaria treatments - are in talks about merging some functions to help combat a financing crunch, their chief executives told Reuters.
The groups – the Global Fund to Fight AIDS, Tuberculosis and Malaria and the vaccine group Gavi – said they had been discussing working more efficiently together for several years, but a massive pull-back on government-funded aid budgets, led by the Trump administration, has given the talks more urgency.
'I think the crisis – and it is a crisis, what we're facing in global health right now – is an impetus to think hard about the shape and structure of the global health ecosystem,' Peter Sands, chief executive of the Global Fund, told Reuters.
Gavi and the Global Fund set up a working group in autumn last year to work more closely together and explore merging some functions, joined by the World Bank's Global Financing Facility for women and girls. The group's work, which is ongoing, has not been previously reported.
'The idea is not to bring these massive structures together, the idea is to work better at the country level… to make life for countries easier,' said Sania Nishtar, Gavi chief executive.
Sands and Nishtar spoke to Reuters during the World Health Organization's annual meeting in Geneva, at which budget cuts and efficiencies were high on the agenda.
Nishtar gave an example of Gavi in Nigeria helping local health officials give children measles and rubella vaccines, while Global Fund supported them giving bed nets to their parents to help prevent malaria. Previously, the two groups might have had separate desks, supply chains, data, staff, logistics, and guidelines, and even warehouses. That should be done better, she said.
Working together on rolling out the malaria vaccine, led by Gavi, alongside other malaria tools like preventive drugs, which the Global Fund manages, had also prompted greater cooperation.
The Global Fund is trying to raise $18 billion for its work from 2027-2029, and Gavi is trying to raise $9 billion for 2026-2030.
Donors told Reuters that they are pushing for efficiencies as they consider how much to pledge to the groups, which have saved millions of lives since beginning work in the early 2000s.
A Gavi spokesperson said it had started a voluntary departure scheme among its 650 staff and consultants and was working to streamline operations. The Global Fund has around 1,200 staff and declined to comment on potential cuts.
Advocates including Bill Gates, a major global health funder through his foundation, said he had been talking to governments about the essential role the two organisations play.
'Being an advocate and making sure the money is well-spent, that is part of my role,' he told Reuters earlier this month. REUTERS
Join ST's Telegram channel and get the latest breaking news delivered to you.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
10 hours ago
- Business Times
Buffett effect still holds as UnitedHealth soars through August
[NEW YORK] The Warren Buffett effect is proving true once again, spurring UnitedHealth Group's reversal this month and giving the Dow Jones Industrial Average a push towards its first closing high since last year. Buffett's Berkshire Hathaway revealed last week that it bought a stake in the health insurer in the second quarter. UnitedHealth shares, which lost more than 50 per cent from the start of 2025 through the end of July, have been on a tear this month, rising more than 20 per cent in August alone and far outperforming any other company in the blue-chip index during that stretch. The stock has added more than 300 points to the Dow in August, accounting for more than 40 per cent of its monthly gain. It has been a welcome boost for the stock-price-weighted benchmark, which hit an intraday record on Tuesday but has yet to close at a new all-time high and has been trounced by other major equity indexes, like the S&P 500 and Nasdaq 100, this year. 'There wasn't a single piece of good news basically this whole year specific to UnitedHealth,' Morningstar analyst Julie Utterback said. 'So having a company like Berkshire Hathaway investing competitively in a managed firm that was attractively valued, that's really a nice vote of confidence.' The 'Buffett Effect' essentially refers to a stock market phenomenon where share prices rise when the legendary investor takes a stake and fall when he exits a position. In this case it's notable because until very recently UnitedHealth was the biggest drag on the Dow this year. Then it reversed direction and quickly went from worst to first. 'Really tough year' 'Investors in UnitedHealth have had a really tough year,' said Utterback, who tracks the stock's decline to early December, when former executive Brian Thompson was fatally shot outside an investor conference in New York. The stock is still down 40 per cent in 2025 and is trading at a little more than US$300. Utterback has a buy rating and US$400 price target on the shares. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Thompson's murder, which was a targeted attack aimed at UnitedHealth's leadership, helped send the Dow on its longest losing streak since the 1970s. At the same time, the insurer's stock fell from the biggest weight in the 30-member index to seventh. But since the Berkshire Hathaway stake was revealed after the market closed on Aug 14, Wall Street has turned incrementally positive on UnitedHealth. And more broadly, investors are starting to see some momentum from the entire health-care sector. Jonathan Krinsky, chief market technician at BTIG, says he's 'sticking with health care for a more defensive posture' and because it's the best-performing sector in the market in August.A As for UnitedHealth, it may be more attractive as a longer-term position. 'If you can take a five-year view (on UnitedHealth), you likely will do well,' analysts at BofA Securities wrote in a note to clients on Monday that was subtitled 'Berkshire is in, should you be?' The bank raised also its price target on the stock to US$325 from US$290. And when it comes to dragging the Dow to a new closing high, the company still needs some help. 'The rest of the stocks still need to be able to rally,' said Matt Maley, chief market strategist at Miller Tabak +, though he added that removing the biggest drag on the index is a positive sign. 'The DJIA is something the individual investor watches more closely than the pros.' BLOOMBERG
Straits Times
a day ago
- Straits Times
Somalia faces diphtheria surge amid vaccine shortages and aid cuts
Sign up now: Get ST's newsletters delivered to your inbox MOGADISHU - Diphtheria cases and deaths have risen sharply this year in Somalia, where the response has been curtailed by vaccine shortages and U.S. aid cuts, Somali officials said. More than 1,600 cases, including 87 deaths, have been recorded, up from 838 cases and 56 deaths in all of 2024, said Hussein Abdukar Muhidin, the general director of Somalia's National Institute of Health. Diphtheria, a bacterial disease that causes swollen glands, breathing problems and fever and mostly affects children, is preventable with a vaccine that became widely available in the mid-20th century. Childhood immunisation rates in Somalia have improved over the past decade, but hundreds of thousands of children are still not fully vaccinated. After fleeing fighting between government forces and Islamist militants in the central Somalia town of Ceeldheere three months ago, all four of Deka Mohamed Ali's children, none of whom was vaccinated, contracted diphtheria. Her 9-year-old daughter recovered, but her 8-year-old son died and two toddlers are now being treated at a hospital in the capital Mogadishu. "My children got sick and I just stayed at home because I did not know it was diphtheria," she told Reuters from the bedside of her 3-year-old son Musa Abdullahi whose throat was swollen to the size of a lemon from the infection. Health Minister Ali Haji Adam said the government had struggled to procure enough vaccines due to a global shortage and that U.S. aid cuts were making it difficult to distribute the doses it had. Top stories Swipe. Select. Stay informed. Singapore What led to Changi Airport runway incident involving 2 China Eastern Airlines planes in Aug 2024 Singapore FairPrice apologises after woman finds worm in salmon bought from Bedok North outlet Singapore CPIB nabs 9 suspects for alleged match-fixing in national basketball league Singapore Live Singapore-raised seafood on sale at 3 Giant supermarkets from Aug 19 Singapore Singapore seals carbon credit deal with Thailand, its first South-east Asian partner Asia Singaporean man sentenced to 72 years' jail in Malaysia for murdering wife and stepson Singapore Court to assess if teen who advertised vapes for sale on WhatsApp can receive probation Before President Donald Trump cut most foreign assistance earlier this year, the United States was the leading humanitarian donor to Somalia, whose health budget is almost entirely funded by donors. "The U.S. aid cut terribly affected the health funds it used to provide to Somalia. Many health centres closed. Mobile vaccination teams that took vaccines to remote areas lost funding and now do not work," said Adam. Muhidin separately echoed his comments about the closures. Overall U.S. foreign assistance commitments to Somalia stand at $149 million for the fiscal year that ends on September 30, compared with $765 million in the previous fiscal year, according to U.S. government statistics. "The United States continues to provide lifesaving foreign assistance in Somalia," a U.S. State Department spokesperson said when asked about the impact of its aid cuts in the country. "America is the most generous nation in the world, and we urge other nations to dramatically increase their humanitarian efforts." Aid group Save the Children said last month that the closure of hundreds of health clinics in Somalia this year due to foreign cuts has contributed to a doubling in the number of combined cases of diphtheria, measles, whooping cough, cholera and severe respiratory infections since mid-April. Besides the U.S., Britain, France, Germany and other major Western donors are also cutting aid budgets. Somalia's government has also faced criticism from doctors and human rights activists for its limited funding of the health sector. In 2024, it allocated 4.8% of its budget to health, down from 8.5% the previous year, Amnesty International said. The health ministry did not respond to a question about that criticism. It has said it is planning to launch a vaccination drive but has not given details when. REUTERS
Business Times
2 days ago
- Business Times
Australian biotech giant CSL to spin off vaccine unit Seqirus, cut 15% of workforce
[SYDNEY] Australian biotech giant CSL said that it will spin off its Seqirus vaccine business into a separately listed company as part of a restructure that will see it reduce its workforce by as much as 15 per cent and cut costs by around US$500 million a year. CSL Seqirus, which makes seasonal influenza vaccines, contributed US$2.2 billion of the firm's total revenue of US$15.6 billion in the 12 months ended Jun 30, the Melbourne-based company said on Tuesday (Aug 19). Net profit rose 17 per cent to US$3 billion, just above analyst estimates of US$2.97 billion. Seqirus will list on the Australian securities exchange by the end of this fiscal year. The spinoff will give Seqirus, which will be chaired by Gordon Naylor, 'autonomy to set an independent strategic direction, including capitalising on potential opportunities that may arise in a highly dynamic vaccines market, as well as reducing complexity, making the business more agile and efficient to manage', CSL said. CSL also closed 22 underperforming US plasma centres this month, and will consolidate its research and development from 11 sites into six. The restructure will unlock US$500 million in annual savings by the end of fiscal 2028, though CSL will incur one-off restructuring costs of US$700 million to US$770 million. While CSL employs around 32,000 people, no firm number was put on the job cuts. Further details on the Seqirus spinoff will be given at CSL's capital markets day on Nov 4 to 6 in the US. CSL also plans to buy back A$750 million (S$626 million) of shares this financial year, the first step in a multi-year buyback. BLOOMBERG
